MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

Rhea-AI Summary

MetaVia (MTVA) announced the acceptance of a pre-clinical data abstract on DA-1241, their novel GPR119 agonist, for poster presentation at the American Diabetes Association's 85th Scientific Sessions. The presentation, titled 'Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH', will be delivered by Dong-A ST Research Center's Lead Research Scientist Yuna Chae. The presentation is scheduled for June 22, 2025, from 12:30-1:30 pm CT at Chicago's McCormick Place Convention Center. The poster will be made available on MetaVia's website and published in the journal Diabetes®.

CAMBRIDGE, Mass., June 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting pre-clinical data on DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has been accepted for a poster presentation at the American Diabetes Association's 85th Scientific Sessions, taking place June 20-23, 2025 at the McCormick Place Convention Center in Chicago, Illinois.

• Title: Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH
• Presenting Author: Yuna Chae, Lead Research Scientist, Dong-A ST Research Center
• Abstract Control Number: 2025-LB-6450
• Session: 22-C Integrated Physiology—Liver
• Presentation Date: Sunday, June 22, 2025
• Presentation Time: 12:30-1:30 pm CT

A copy of the poster will be available on the Posters section of the MetaVia website after the presentation. Additionally, the poster will be published online on the journal, Diabetes®, website.

About DA-1241
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-poster-presentation-on-da-1241-at-the-adas-85th-scientific-sessions-302472875.html

SOURCE MetaVia Inc.

FAQ

What will MetaVia (MTVA) present at the ADA Scientific Sessions 2025?

MetaVia will present pre-clinical data on DA-1241, a novel GPR119 agonist, focusing on its hepatoprotective effects in combination with efruxifermin in a mouse model of MASH.

When and where is MetaVia's (MTVA) poster presentation at ADA 2025?

The presentation will take place on Sunday, June 22, 2025, from 12:30-1:30 pm CT at the McCormick Place Convention Center in Chicago, Illinois.

Who is presenting MetaVia's (MTVA) research at ADA 2025?

Yuna Chae, Lead Research Scientist from Dong-A ST Research Center, will present the research.

Where can I find MetaVia's (MTVA) ADA 2025 poster after the presentation?

The poster will be available in the Posters section of MetaVia's website and published online on the journal Diabetes® website.